Aldosterone as a key mediator of the cardiometabolic syndrome in primary aldosteronism: an observational study
The DOI matches its Crossref record; 41 of the 42 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Primary aldosteronism (PA) is characterized by the onset of both cardiac and gluco-metabolic alterations. The aim of this study was to evaluate the impact of aldosterone excess on the development of such complications, and the effects of surgical and pharmacological treatment on their long-term outcome. METHODS: We prospectively re-examined 61 patients: 25 with aldosterone-producing adenoma (APA), after surgery, and 36 patients with idiopathic hyperaldosteronism (IHA) on pharmacological treatment. The lipid, fasting and dynamic glucose profiles and the echocardiographic parameters were evaluated at diagnosis and at follow-up. RESULTS: After adrenalectomy all patients had normalization of aldosterone levels and were cured of hypokalaemia, and a resolution of hypertension was achieved in 12 of 25 patients. APA patients showed a significant reduction of both plasma glucose (P=0.017) and insulin levels (P=0.001) after 75 g oral glucose tolerance test. Stabilization of glucose metabolism complications was observed in IHA patients. Multiple regression analysis at diagnosis showed a positive correlation between homeostasis model assessment (HOMA) insulin resistance index and HOMA beta cell and serum aldosterone levels in both APA and IHA. Echocardiographic parameters were improved in both APA and IHA at follow-up and the difference was statistically significant for left ventricular mass index (P=0.017) and interventricular septum thickness (P=0.007) in APA patients. CONCLUSIONS: The removal of aldosterone excess in APA patients induces the regression of both cardiac and gluco-metabolic complications, indicating aldosterone as a main determinant of such alterations. In IHA patients the medical treatment seems to avoid the possible progression of the these alterations that appear to be stable.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Primary aldosteronism (PA) is associated with increased risk for dysglycemia.”
From Insulin sensitivity and pancreatic β-cell function in patients with primary aldosteronism (2021) · cites this paper as [8]
In the citing paper
“However, the effects of hyperaldosteronism on insulin sensitivity and β-cell function are unclear.”
From Insulin sensitivity and pancreatic β-cell function in patients with primary aldosteronism (2021) · cites this paper as [8]
In the citing paper
“However, when compared with normotensive cohorts, reduced insulin sensitivity has been reported in PA patients [19,9,20,13,8,21,22].”
From Insulin sensitivity and pancreatic β-cell function in patients with primary aldosteronism (2021) · cites this paper as [8]
In the citing paper
“In patients with primary aldosteronism (PA), resection of aldosteroneproducing tumors and pharmacological treatment both reduced blood insulin and glucose levels, suggesting an improvement in insulin sensitivity (, ).”
From Glucose Metabolism Abnormalities in Cushing Syndrome: From Molecular Basis to Clinical Management (2017) · cites this paper as [167]
Citations
Cites
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502
Follow-up report on the diagnosis of diabetes mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus* (2003) · Diabetes Care · doi:10.2337/diacare.26.11.3160 · Cited by 3,784
(2003) · Journal of Hypertension · doi:10.1097/00004872-200306000-00001 · Cited by 3,027
Mancia, G., Rosei, E. A., Cífková, R., DeBacker, G., Erdine, S. E., Fagard, R., Farsang, C., Heagerty, A. M., Kawecka-Jaszcs, K., Kiowski, W., et al. (2003) · Lirias · doi:10.1097/01.hjh.0000059051.65882.32 · Cited by 2,601
Standards of Medical Care in Diabetes–2006
American Diabetes Association (2006) · Diabetes Care · doi:10.2337/diacare.29.s1.06.s4 · Cited by 1,885
Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism
Milliez, P., Girerd, X., Plouin, P.-F., Blacher, J., Safar, M. E., & Mourad, J.-J. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.01.015 · Cited by 1,547
(1999) · The Lancet · doi:10.1016/s0140-6736(98)12131-1 · Cited by 1,313
Borch‐Johnsen, K., Neil, A., Balkau, B., Larsen, S. H., Nissinen, A. E. T., Pekkanen, J., Keinanen-Kiukaanniemi, S. M., Hiltunen, L. A., Kivelä, S., Tuomilehto, J. O., et al. (1999) · The Lancet · Cited by 1,272
Mulatero (2004) · doi:10.1210/jc.2003-031337 · Cited by 961
Rates and tissue sites of non-insulin- and insulin-mediated glucose uptake in humans
Baron, A. D., Brechtel, G., Wallace, P., & Edelman, S. V. (1988) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1988.255.6.e769 · Cited by 642
de Vegt, F., Dekker, J. M., Ruhé, H. G., Stehouwer, C. D. A., Nijpels, G., Bouter, L. M., & Heine, R. J. (1999) · Diabetologia · doi:10.1007/s001250051249 · Cited by 613
Balkau, B., Shipley, M., Jarrett, R. J., Pyörälä, K., Pyörälä, M., Forhan, A., & Eschwège, E. (1998) · Diabetes Care · doi:10.2337/diacare.21.3.360 · Cited by 598
Cavalot, F., Petrelli, A., Traversa, M., Bonomo, K., Fiora, E., Conti, M., Anfossi, G., Costa, G., & Trovati, M. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-1005 · Cited by 569
Devereux, R. B. (1987) · Hypertension · doi:10.1161/01.hyp.9.2_pt_2.ii19 · Cited by 550
Bonora, E., & Muggeo, M. (2001) · Diabetologia · doi:10.1007/s001250100020 · Cited by 420
Primary Aldosteronism: Factors Associated with Normalization of Blood Pressure after Surgery
Sawka, A. M., Young, W. F., Thompson, G. B., Grant, C. S., Farley, D. R., Leibson, C., & van Heerden, J. A. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-135-4-200108210-00010 · Cited by 347
Changes in Left Ventricular Anatomy and Function in Hypertension and Primary Aldosteronism
Rossi, G. P., Sacchetto, A., Visentin, P., Canali, C., Graniero, G. R., Palatini, P., & Pessina, A. C. (1996) · Hypertension · doi:10.1161/01.hyp.27.5.1039 · Cited by 328
Rossi, G. P. (2001) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.86.3.1083 · Cited by 289
Ganguly, A. (1998) · New England Journal of Medicine · doi:10.1056/nejm199812173392507 · Cited by 277
Remodeling of the Left Ventricle in Primary Aldosteronism Due to Conn’s Adenoma
Rossi, G. P., Sacchetto, A., Pavan, E., Palatini, P., Graniero, G. R., Canali, C., & Pessina, A. C. (1997) · Circulation · doi:10.1161/01.cir.95.6.1471 · Cited by 273
The renin-angiotensin-aldosterone system, glucose metabolism and diabetes
Giacchetti, G., Sechi, L. A., Rilli, S., & Carey, R. M. (2005) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2005.02.003 · Cited by 267
Self-citationEffect of experimental potassium deficiency on glucose and insulin metabolism
Rowe, J. W., Tobin, J. D., Rosa, R. M., & Andres, R. (1980) · Metabolism · doi:10.1016/0026-0495(80)90074-8 · Cited by 226
Postchallenge Hyperglycemia and Mortality in a National Sample of U.S. Adults
Saydah, S. H., Miret, M., Sung, J., Varas, C., Gause, D., & Brancati, F. L. (2001) · Diabetes Care · doi:10.2337/diacare.24.8.1397 · Cited by 221
Irony, I., Kater, C. E., Biglieri, E. G., & Shackleton, C. H. L. (1990) · American Journal of Hypertension · doi:10.1093/ajh/3.7.576 · Cited by 164
Giacchetti, G., Ronconi, V., Lucarelli, G., Boscaro, M., & Mantero, F. (2006) · Journal of Hypertension · doi:10.1097/01.hjh.0000217857.20241.0f · Cited by 154
Self-citationAldosterone as a cardiovascular risk factor
Rossi, G. P., Boscaro, M., Ronconi, V., & Funder, J. W. (2005) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2005.02.010 · Cited by 148
Self-citationHyperglycaemic effect of nifedipine.
Charles, S., Ketelslegers, J., Buysschaert, M., & Lambert, A. (1981) · BMJ · doi:10.1136/bmj.283.6283.19 · Cited by 138
Aldosterone as a Cardiovascular Risk Factor
Yoo, S. J. (2007) · Journal of Korean Endocrine Society · doi:10.3803/jkes.2007.22.1.8 · Cited by 112
Aldosterone: Direct Effects on and Production by the Heart
White, P. C. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030373 · Cited by 97
The effect of aldosterone on glucose metabolism
Corry, D. B., & Tuck, M. L. (2003) · Current Hypertension Reports · doi:10.1007/s11906-003-0065-2 · Cited by 90
Insulin action in primary hyperaldosteronism before and after surgical or pharmacological treatment
Šindelka, G., Widimský, J., Haas, T., Prázný, M., Hilgertová, J., & Škrha, J. (2012) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-0032-1329211 · Cited by 75
Aldosterone Function in Diabetes Mellitus: Effects on Cardiovascular and Renal Disease
McFarlane, S. I., & Sowers, J. R. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021443 · Cited by 67
YAMASHITA, R., KIKUCHI, T., MORI, Y., AOKI, K., KABURAGI, Y., YASUDA, K., & SEKIHARA, H. (2004) · Endocrine Journal · doi:10.1507/endocrj.51.243 · Cited by 55
Low testosterone and insulin resistance in hypertension-prone men.
Endre, T., Mattiasson, I., Berglund, G., & Hulthén, U. L. (1996) · PubMed · Cited by 52
Does insulin resistance participate in an impaired glucose tolerance in primary aldosteronism?
Shimamoto, K., Shiiki, M., Ise, T., Miyazaki, Y., Higashiura, K., Fukuoka, M., Hirata, A., Masuda, A., Nakagawa, M., & Iimura, O. (1994) · PubMed · Cited by 50
Lind, L., Berne, C., Pollare, T., & Lithell, H. (1995) · PubMed · Cited by 46
Haluzík, M., Šindelka, G., Widimsky, J., Jr., Prázný, M., Zelinka, T., & Škrha, J. (2002) · Journal of Human Hypertension · doi:10.1038/sj.jhh.1001292 · Cited by 37
Ueshiba, H., & Miyachi, Y. (2004) · Internal Medicine · doi:10.2169/internalmedicine.43.561 · Cited by 34
Postprandial Hyperglycemia and Cardiovascular Disease
Gerich, J. E. (2006) · Endocrine Practice · doi:10.4158/ep.12.s1.47 · Cited by 32
Campión, J., Maestro, B., Molero, S., Dávila, N., Carranza, M. C., & Calle, C. (2002) · Cell Biochemistry and Function · doi:10.1002/cbf.970 · Cited by 28
Carranza, M. C., Torres, A., & Calle, C. (1991) · PubMed · Cited by 16
Cited by
Sowers, J. R., Whaley-Connell, A., & Epstein, M. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-11-200906020-00005 · Cited by 351
“In patients with primary hyperaldosteronism, resection of aldosterone-producing tumors and pharmacologic treatment both decrease blood insulin and glucose levels, which indicates an improvement in insulin sensitivity (37, 38).”
Aldosterone and end-organ damage
Brown, N. J. (2005) · Current Opinion in Nephrology and Hypertension · doi:10.1097/01.mnh.0000165889.60254.98 · Cited by 320
Aldosterone and end-organ damage
Marney, A. M., & Brown, N. J. (2007) · Clinical Science · doi:10.1042/cs20070123 · Cited by 212
Primary aldosteronism: cardiovascular, renal and metabolic implications
Rossi, G.-P., Sechi, L. A., Giacchetti, G., Ronconi, V., Strazzullo, P., & Funder, J. W. (2008) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2008.01.006 · Cited by 204
Self-citationIngelsson, E., Pencina, M. J., Tofler, G. H., Benjamin, E. J., Lanier, K. J., Jacques, P. F., Fox, C. S., Meigs, J. B., Levy, D., Larson, M. G., et al. (2007) · Circulation · doi:10.1161/circulationaha.107.708537 · Cited by 195
Metadata
- Authors
- Giacchetti, G., Ronconi, V., Turchi, F., Agostinelli, L., Mantero, F., Rilli, S., & Boscaro, M.
- Affiliations
- Marche Polytechnic University (IT)
- University of Padua (IT)
- Corresponding author
- Giacchetti, Gilberta
- Venue
- Journal of Hypertension
- Published
- 2007-01
- Volume
- 25
- Issue
- 1
- Pages
- 177-186
- ISSN
- 0263-6352 (ISSN-L)
- OpenAlex
- W1992509588
- Semantic Scholar
- 0723dc5409b5d4599f90cc6db27b50af9eba3cb9
- Cited by
- 196
- References
- 42
- Citations by year
- 2026: 6 · 2025: 6 · 2024: 5 · 2023: 5 · 2022: 11 · 2021: 7 · 2020: 11 · 2019: 11 · 2018: 5 · 2017: 7 · 2016: 8 · 2015: 13 · 2014: 7 · 2013: 13 · 2012: 20
- FWCI
- 9.10
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Hypertension (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
- Health Sciences › Medicine › Nephrology › Potassium and Related Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Keywords
- primary aldosteronism, aldosterone, cardiometabolic syndrome, aldosterone-producing adenoma, idiopathic hyperaldosteronism, adrenalectomy, insulin resistance, beta-cell function, glucose metabolism, left ventricular hypertrophy, hypertension, hypokalemia, mineralocorticoid receptor antagonists
- MeSH terms
- Adenoma, Adrenal Gland Neoplasms, Adrenalectomy, Aldosterone, Mineralocorticoid Receptor Antagonists, Antihypertensive Agents, Blood Glucose, Blood Pressure, Female, Follow-Up Studies, Heart Diseases, Humans, Hyperaldosteronism, Hypertension, Insulin, Insulin Resistance, Longitudinal Studies, Male, Middle Aged, Prospective Studies, Renin-Angiotensin System, Time Factors, Linear Models, Ventricular Function, Left, Glucose Metabolism Disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.